跳至主要内容
临床试验/NCT00530387
NCT00530387已完成不适用

A Prospective, Open, Multi-Centre Photopatch Test Study of Patients Suspected of Photoallergy to Organic Sunscreens and Topical Nonsteroidal Anti-inflammatory Drugs Used Within Europe.

NHS Tayside2 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2008年7月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
NHS Tayside
入组人数
1,000
试验地点
2
主要终点
The development of a photocontact allergic skin response to sunscreen filters and topical NSAIDs, as graded by the ICDRG scale.

研究概览

简要总结

It is known that people can develop an allergic skin reaction to a substance which is placed on the skin and then subjected to sunlight. This process is called Photocontact allergic dermatitis. It is known that people can develop Photocontact allergic dermatitis to sunscreen chemicals (filters) and also cream forms of pain-killing drugs called nonsteroidal anti-inflammatory drugs (NSAIDs).

The purpose of this study is to determine the frequency of Photocontact allergic dermatitis to 19 sunscreen filters and 5 topical NSAIDs in 1,000 European patients who present to a dermatologist with a sun-exposed site dermatitis.

Each participant will have the 24 test agents plus one control of petrolatum applied to the skin of the back for 24 or 48 hours. After removal of the substances, the area of skin will be exposed to a precise amount of ultraviolet-A light. The area is then assessed 24, 48 and 72 hours later to see if a photocontact allergic reaction has occured. This method is known as photopatch testing.

The study will run for one year, during which time it is planned to recruit 1,000 patients.

详细描述

Specific Intervention Names:

  • Butyl-methoxy-dibenzoylmethane
  • Homosalate
  • Methylbenzylidene camphor
  • Benzophenone-3
  • Octyl methoxycinnamate
  • Phenylbenzimidazol sulfonic acid
  • Benzophenone 4
  • Drometrizole trisiloxane
  • Octocrylene
  • Octyl salicylate
  • Octyl triazone
  • Isoamyl-p-methoxycinnamate
  • Terephtalidene dicamphor sulphonic acid (Mexoryl SX)
  • Tinosorb S
  • Tinosorb M
  • Univul A+
  • Neoheliopan AP
  • Uvasorb HEB
  • Parsol SLX
  • Ketoprofen 1%
  • Etofenamate 2%
  • Piroxicam 1%
  • Diclofenac 5%
  • Ibuprofen 5 %

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female aged 18 years or older.
  • Have sufficient cognitive capacity to give written informed consent.
  • Have an eruption on photo-exposed sites, which is to be further classified using one (or more) of the categories below:
  • Known photosensitivity disease
  • History of sunscreen reaction
  • Sun exposed site dermatitis during summer months
  • Any sun exposed site dermatitis problem

排除标准

  • Male or female aged 17 years or younger
  • Have had potent topical steroid applied to the photopatch test site on the back in the previous 5 days. (This potentially suppresses reactions which would otherwise have been visible)
  • Have skin disease on the back which is too active to allow testing. (This obscures the sites of testing by making differentiation between a positive result and other skin disease difficult)
  • Be prescribed systemic immunosuppressant medication (e.g. prednisolone, methotrexate, azathioprine, ciclosporin) (This potentially suppresses reactions which would otherwise have been visible)
  • Be taking any photoactive medicine (for example thiazides, sulphonamide derivatives, amiodarone, fluoroquinolones, chlorpromazine, NSAIDs, quinine). (This is a relative exclusion. Many centres may wish to go ahead despite such medication).

结局指标

主要结局

The development of a photocontact allergic skin response to sunscreen filters and topical NSAIDs, as graded by the ICDRG scale.

时间窗: Within 72 hours of irradiation of patch test site

次要结局

未报告次要终点

研究者

发起方
NHS Tayside
申办方类型
Other Gov

研究点 (2)

Loading locations...

相似试验